Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.64 |
| ▸ | PPARG | P37231 | 3/20 | 0.64 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.64 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202030 | 0.90 | SQOR (0.53) | HPGDKDM4ENPSR1PPARGNCOA2 | |
| SCHEMBL6255059 | 0.82 | ADORA1 (0.64) | HPGDKDM4ENPSR1PPARGNCOA2 | |
| SCHEMBL6252443 | 0.77 | KDM4E (0.55) | HPGDKDM4ENPSR1PPARGSQOR | |
| SCHEMBL12430337 | 0.73 | NPSR1 (0.35) | HPGDKDM4ENPSR1PPARGNCOA2 | |
| SCHEMBL12430347 | 0.71 | SQOR (0.41) | HPGDKDM4ENPSR1PPARGNCOA2 | |
| SCHEMBL29442440 | 0.70 | SQOR (1.00) | HPGDKDM4ENPSR1SQORADORA1 | |
| SCHEMBL22208351 | 0.70 | SQOR (1.00) | HPGDKDM4ENPSR1SQORADORA1 | |
| SCHEMBL31120375 | 0.69 | ADORA1 (0.78) | HPGDKDM4ENPSR1PPARGNCOA2 | |
| SCHEMBL11365280 | 0.67 | L3MBTL1 (0.76) | HPGDKDM4ENPSR1PPARGNCOA2 | |
| SCHEMBL29649220 | 0.67 | L3MBTL1 (1.00) | HPGDKDM4ENPSR1PPARGNCOA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846402-B1 | 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1846402-A1 | 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006063805-A1 | 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES | BAYER SCHERING PHARMA AKTINGESELLSCHAFT (DE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | MAP4K2, ABL1, MAP4K3 | HPGD 2273/4885KDM4E 1340/4885NPSR1 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.